Abstract: The present invention relates to compounds of formula (I), in which A, B, X, Y, R1, R2, R3 and n have the meanings indicated in the claims. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Abstract: A process for the preparation of a compound of the formula wherein the substituents are defined as set forth in the specification comprising reacting a compound of the formula with a 2-halo-3-quinoline-methanol of the formula to obtain a compound of the formula which is then cyclized to form the compound of Formula I.

Abstract: The present invention relates to novel 5-pyrimidinecarboxamide derivatives and the pharmaceutical compositions containing said derivatives, and more specifically, to 5-pyrimidinecarboxamide derivatives and their pharmacutically able salts, the process for preparing them, and the pharmaceutical compositions containing said compounds as active ingredients. In particular, said 5-pyrimidinecarboxamide derivatives of the present invention, due to their inhibitory activity against the proliferation of human immunodeficiency virus (HIV) as well as hepatitis B virus (HBV), can be used as a therapeutic agent as well as a preventive agent for hepatitis B and acquired immune deficiency syndrome (AIDS).

Abstract: A prefabricated joint is employed for the prosthetic joint. The joint includes prefabricated socket, ball, and capsule. The capsule is attached from the ball to the socket. The capsule seals the area between the ball and socket and prevents wear debris from entering the body cavity. In the case of the hip joint, the doctor need only attach the prefabricated unit to the femoral unit to connect the prosthetic joint after the prefabricated unit and femoral unit have been placed into the acetabular and femur, respectively.

Abstract: The invention concerns novel 2-aminopyridine derivatives having an activity inhibiting NO-synthase enzymes producing nitrogen monoxide NO and/or trapping reactive forms of oxygen, the methods for preparing them, pharmaceutical compositions containing them and their therapeutic uses, particularly their use as NO-synthase inhibitors and for trapping reactive forms of oxygen whether selectively or not.

Abstract: The method of treating narcotic withdrawal symptoms in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a compound having anti-mineralocorticoid activity sufficient to treat narcotic withdrawal symptoms.

Abstract: The invention concerns the field of pharmaceutics and dietetics. More particularly, the invention concerns pharmaceutical and/or dietetic mushroom-based compositions, characterised in that they contain one or several edible mushrooms with therapeutic properties and chitosan.

Abstract: The invention concerns compounds for treating pathological conditions or diseases wherein one (or several) somatostatin receptors is (are) involved, corresponding to general formula (I) wherein: R1 represents in particular a carbocyclic or heterocyclic aryl radical optionally substituted or a non-aromatic heterocyclic radical optionally substituted; R2 represents H, alkyl or aryl optionally substituted; R3 represents H or —(CH2)p—Z3, Z3 representing in particular alkyl, cycloalkyl, bis-arylalkyl or di-aryalkyl, —Y1—(CH2)p-phenyl-(X1)n, carbocyclic or heterocyclic aryl optionally substituted, a non-aromatic heterocyclic radical optionally substituted, X1, every time it is present, being independently selected in particular among the radicals H, Cl, F, Br, I, CF3, NO2, OH, NH2, CN, N3, —OCF3, alkyl, alkoxy, —S-alkyl, —(CH2)p—NH2, —(CH2)p—NH-alkyl, —(CH2)p—N-alkyl; Y1 represents O, S, NH or is not present; R4 represents —(CH2)p—Z

Abstract: A layer formation method is disclosed which comprises supplying gas to a discharge space, exciting the supplied gas at atmospheric pressure or at approximately atmospheric pressure by applying a high frequency electric field across the discharge space, and exposing a substrate to the excited gas, wherein the high frequency electric field is an electric field in which a first high frequency electric field and a second high frequency electric field are superposed, frequency &ohgr;2 of the second high frequency electric field is higher than frequency &ohgr;1 of the first high frequency electric field, strength V1 of the first high frequency electric field, strength V2 of the second high frequency electric field and strength IV of discharge starting electric field satisfy relationship V1≧IV>V2 or V1>IV≧V2, and power density of the second high frequency electric field is not less than 1 W/cm2.

Abstract: The present invention is directed to polymer conjugates of biologically active agents and methods of preparing the same. In preferred aspects of the invention, the conjugates are of the formula wherein G is a linear or branched polymer residue such as a polyethylene glycol and B is a residue of an amine-containing or a hydroxyl-containing biologically active moiety such as Ara-C.

Abstract: A toner for forming a color image comprises chromatic toners and a black toner is disclosed. Each of the toners is produced by polymerization of a polymerizable monomer in an aqueous medium, the difference of re-dispersion electro-conductivity of each of the toners is within the range of from 0.8 to 12 &mgr;s/cm, the number of free colorant particles on the black toner surface is less than 9 per 500 toner particles, and a light absorbance at 500 nm of a black toner dispersion is nor more than 0.08.

Abstract: The present invention is an apparatus for intermittently providing oral medications to a patient being fed through a feeding tube, the apparatus having a dosage vessel, which preferably can be capped or sealed, and a secure fluid path to a tubing connector for connecting to the indwelling feeding tube.

Abstract: The present invention relates to optically active quinoline carboxylic acid derivatives, their pharmaceutically acceptable salts, their solvates, and a process for the preparation thereof. More specifically, the present invention relates to optically active quinoline carboxylic acid derivatives containing 4-aminomethyl-4methyl-3-(Z)-alkoxyiminopyrrolidine substituents causing optical activity at the 7-position of the quinolone nuclei. As the compounds of the present invention have superior antibacterial activity and pharmacokinetic profiles to their enantiomers, their racemates and conventional antibacterial agents, with nearly no phototoxicity, the compounds of this invention are useful for antibacterial agents.

Abstract: Indole-3-succinic acid and its derivatives are used as auxins. They are administered to plants to promote root growth.

Abstract: Disclosed is a planographic printing plate precursor comprising a support, and provided thereon, an image forming layer, a first outermost layer on the image forming layer side and a second outermost layer on the side of the support opposite the first outermost layer, the first and second outermost layers containing a lubricant component, which is manufactured either by a method comprising the steps of preparing a planographic printing plate precursor comprising a support and provided thereon, an image forming layer so that only the first outermost layer contains a lubricant component and winding the resulting precursor in the roll form, or by a method comprising the steps of preparing a planographic printing plate precursor comprising a support and provided thereon, an image forming layer so that only the second outermost layer contains a lubricant component and winding the resulting precursor in the roll form.

Abstract: Disclosed is a light sensitive composition containing a compound represented by the following formula (1): wherein R1, R2 and R3 independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, provided that R1 and R2 may combine with each other to form a ring or R2 and R3 may combine with each other to form a ring.

Abstract: A silver halide color photographic material is disclosed, comprising support having thereon a yellow image forming layer, a magenta image forming layer and a cyan image forming layer, each of which contains light sensitive silver, halide, wherein when the photographic material having been exposed to light for 10−10 to 10−3 sec. per pixel and processed, an effective tone range of a color image obtained in each of the color image forming layers is 0.65 to 0.84.

Abstract: The present invention relates to new heterocyclic derivatives having an inhibitory activity on calpains and/or a trapping activity on reactive oxygen species, of formula in which A, X, Y, R1, R2 and Het represent variable groups. The invention also relates to their preparation methods, the pharmaceutical preparations containing them and their use for therapeutic purposes, in particular as inhibitors of calpains and/or traps of reactive oxygen species, selectively or non-selectively.

Abstract: An ink-jet image recording method is disclosed. In the method an aqueous ink containing a colored particles comprising a colorant and a resin is employed, and following Formula 1 is satisfied; 15≦w≦150  Formula 1 wherein, w is a parameter expressed by following Formula 2; w=[(dm+ds)/{(NV×vd)/r3}]×10,000  Formula 2 wherein, ds is a recording density in dpi in a moving direction of the recording medium and dm is a recording density in dpi in a direction perpendicular to the moving direction of the recording medium, NV is the colored particle content in the ink in weight percent, vd is a volume average radius in meter of the colored particles and r is radius in meter of the ink droplet.